This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Turning translational academic research into medicines for patients with genetic diseases



BridgeBio is a pharmaceutical company that finds, develops and delivers breakthrough medicines for genetic diseases. Founded in 2015 by a team of industry veterans, the company has built a portfolio of over 30 development programmes ranging from discovery to Phase 3 clinical trials with two approved products. The company’s therapeutic areas include genetic dermatology, oncology, cardiology, neurology and endocrinology.

Find out more at this webinar which forms part of the seminars series focusing on the interface of academia and industry managed by the University of Oxford Medical Sciences Division.

Further information and booking details

Event Types: Partner event